Banques de tissus : Questions médicales fréquentes
Nom anglais: Tissue Banks
Descriptor UI:D014015
Tree Number:N02.278.065.900
Termes MeSH sélectionnés :
Controlled Substances
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Banques de tissus : Questions médicales les plus fréquentes",
"headline": "Banques de tissus : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Banques de tissus : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Banques de tissus"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Biobanques",
"url": "https://questionsmedicales.fr/mesh/D018070",
"about": {
"@type": "MedicalCondition",
"name": "Biobanques",
"code": {
"@type": "MedicalCode",
"code": "D018070",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Banques d'os",
"alternateName": "Bone Banks",
"url": "https://questionsmedicales.fr/mesh/D018586",
"about": {
"@type": "MedicalCondition",
"name": "Banques d'os",
"code": {
"@type": "MedicalCode",
"code": "D018586",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065.900.205"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Banques des yeux",
"alternateName": "Eye Banks",
"url": "https://questionsmedicales.fr/mesh/D005125",
"about": {
"@type": "MedicalCondition",
"name": "Banques des yeux",
"code": {
"@type": "MedicalCode",
"code": "D005125",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N02.278.065.900.400"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Banques de tissus",
"alternateName": "Tissue Banks",
"code": {
"@type": "MedicalCode",
"code": "D014015",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Victoria Stadler Tasca Ribeiro",
"url": "https://questionsmedicales.fr/author/Victoria%20Stadler%20Tasca%20Ribeiro",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Luciana Cristina Wollmann",
"url": "https://questionsmedicales.fr/author/Luciana%20Cristina%20Wollmann",
"affiliation": {
"@type": "Organization",
"name": "Human Tissues Bank, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Paula Hansen Suss",
"url": "https://questionsmedicales.fr/author/Paula%20Hansen%20Suss",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil."
}
},
{
"@type": "Person",
"name": "Felipe Francisco Tuon",
"url": "https://questionsmedicales.fr/author/Felipe%20Francisco%20Tuon",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil. felipe.tuon@pucpr.br."
}
},
{
"@type": "Person",
"name": "Giulia Montagner",
"url": "https://questionsmedicales.fr/author/Giulia%20Montagner",
"affiliation": {
"@type": "Organization",
"name": "Fondazione Banca dei Tessuti del Veneto (FBTV), 31100 Treviso, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35987353",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neuropharm.2022.109220"
}
},
{
"@type": "ScholarlyArticle",
"name": "Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis.",
"datePublished": "2023-01-30",
"url": "https://questionsmedicales.fr/article/36738634",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugalcdep.2023.109788"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews.",
"datePublished": "2024-05-07",
"url": "https://questionsmedicales.fr/article/38715038",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-024-11040-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of mandatory COVID-19 shelter-in-place order on controlled substance use among rural versus urban communities in the United States.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35710976",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jrh.12688"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cardiopulmonary and muscular effects of different doses of high-intensity physical training in substance use disorder patients: study protocol for a block allocated controlled endurance and strength training trial in an inpatient setting.",
"datePublished": "2022-09-27",
"url": "https://questionsmedicales.fr/article/36167363",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-061014"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Établissements, main d'oeuvre et services de soins de santé",
"item": "https://questionsmedicales.fr/mesh/D005159"
},
{
"@type": "ListItem",
"position": 3,
"name": "Établissements de santé",
"item": "https://questionsmedicales.fr/mesh/D006268"
},
{
"@type": "ListItem",
"position": 4,
"name": "Biobanques",
"item": "https://questionsmedicales.fr/mesh/D018070"
},
{
"@type": "ListItem",
"position": 5,
"name": "Banques de tissus",
"item": "https://questionsmedicales.fr/mesh/D014015"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Banques de tissus - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Banques de tissus",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Banques de tissus",
"description": "Comment sont diagnostiquées les maladies nécessitant des tissus ?\nQuels tests sont utilisés pour évaluer la qualité des tissus ?\nLes banques de tissus effectuent-elles des diagnostics ?\nQuels critères sont utilisés pour sélectionner les tissus ?\nComment les tissus sont-ils prélevés pour analyse ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Banques de tissus",
"description": "Quels symptômes peuvent indiquer un besoin de greffe de tissu ?\nLes maladies liées aux tissus présentent-elles des symptômes spécifiques ?\nComment les symptômes influencent-ils le choix des tissus ?\nLes symptômes peuvent-ils varier selon le donneur de tissu ?\nQuels symptômes sont associés aux rejets de greffe ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Banques de tissus",
"description": "Comment prévenir les infections lors de greffes ?\nQuelles mesures sont prises pour éviter le rejet ?\nLes banques de tissus effectuent-elles des tests de dépistage ?\nComment sensibiliser le public sur le don de tissus ?\nQuelles sont les recommandations pour les donneurs potentiels ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Banques de tissus",
"description": "Quels traitements utilisent des tissus de banques ?\nComment les tissus sont-ils préparés pour les traitements ?\nLes banques de tissus participent-elles à la recherche ?\nQuels sont les risques associés aux traitements par greffe ?\nLes traitements par tissus sont-ils toujours efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Banques de tissus",
"description": "Quelles complications peuvent survenir après une greffe ?\nComment gérer les complications post-greffe ?\nLes complications varient-elles selon le type de tissu ?\nQuels signes indiquent une complication après greffe ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Banques de tissus",
"description": "Quels facteurs augmentent le risque de rejet ?\nLe tabagisme influence-t-il le succès des greffes ?\nComment l'âge affecte-t-il le don de tissus ?\nLes antécédents médicaux influencent-ils le don de tissus ?\nQuels comportements à risque affectent le don de tissus ?",
"url": "https://questionsmedicales.fr/mesh/D014015?mesh_terms=Controlled+Substances&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment sont diagnostiquées les maladies nécessitant des tissus ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies sont diagnostiquées par des examens cliniques, imageries et analyses de tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la qualité des tissus ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests histologiques et microbiologiques sont effectués pour évaluer la qualité."
}
},
{
"@type": "Question",
"name": "Les banques de tissus effectuent-elles des diagnostics ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne diagnostiquent pas, mais fournissent des tissus pour des diagnostics."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour sélectionner les tissus ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont sélectionnés selon des critères de qualité, d'origine et d'usage prévu."
}
},
{
"@type": "Question",
"name": "Comment les tissus sont-ils prélevés pour analyse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont prélevés par biopsie ou lors de chirurgies, sous conditions stériles."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un besoin de greffe de tissu ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la douleur chronique ou la défaillance d'organe peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Les maladies liées aux tissus présentent-elles des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque maladie peut avoir des symptômes spécifiques selon le type de tissu affecté."
}
},
{
"@type": "Question",
"name": "Comment les symptômes influencent-ils le choix des tissus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aident à déterminer le type de tissu nécessaire pour le traitement approprié."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier selon le donneur de tissu ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'état de santé du donneur et de son historique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux rejets de greffe ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la douleur, la fièvre et l'inflammation peuvent indiquer un rejet."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections lors de greffes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des protocoles stricts de stérilisation et de suivi post-greffe sont essentiels."
}
},
{
"@type": "Question",
"name": "Quelles mesures sont prises pour éviter le rejet ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des immunosuppresseurs sont administrés pour réduire le risque de rejet après greffe."
}
},
{
"@type": "Question",
"name": "Les banques de tissus effectuent-elles des tests de dépistage ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles effectuent des tests pour dépister les maladies transmissibles chez les donneurs."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser le public sur le don de tissus ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et d'éducation sont menées pour encourager le don de tissus."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les donneurs potentiels ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les donneurs doivent être en bonne santé et respecter les critères d'éligibilité établis."
}
},
{
"@type": "Question",
"name": "Quels traitements utilisent des tissus de banques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les greffes de peau, de cornée et d'organes utilisent des tissus provenant de banques."
}
},
{
"@type": "Question",
"name": "Comment les tissus sont-ils préparés pour les traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tissus sont stérilisés, conservés et parfois modifiés pour s'adapter aux traitements."
}
},
{
"@type": "Question",
"name": "Les banques de tissus participent-elles à la recherche ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des tissus pour la recherche sur les maladies et les traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés aux traitements par greffe ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent le rejet, les infections et les complications liées à l'anesthésie."
}
},
{
"@type": "Question",
"name": "Les traitements par tissus sont-ils toujours efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend de nombreux facteurs, y compris la compatibilité et l'état du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une greffe ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le rejet, les infections et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications post-greffe ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des traitements appropriés sont nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de tissu ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon le type de tissu greffé et l'état du patient."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication après greffe ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la douleur accrue, la fièvre ou l'inflammation peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une bonne préparation et un suivi rigoureux."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de rejet ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la compatibilité tissulaire, l'âge et l'état de santé général du patient."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le succès des greffes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut compromettre la guérison et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Comment l'âge affecte-t-il le don de tissus ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer la qualité des tissus et la décision d'accepter un don."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le don de tissus ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies transmissibles peuvent rendre un donneur inéligible."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque affectent le don de tissus ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements comme l'usage de drogues ou des relations sexuelles non protégées peuvent affecter l'éligibilité."
}
}
]
}
]
}
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, ly...
Opioid overdoses are a leading cause of preventable death in the United States. There is limited research linking decedents' receipt of controlled substances and presence of controlled substances on p...
We linked data on opioid-detected deaths in Connecticut between May 3, 2016, and December 31, 2017 from the Office of the Chief Medical Examiner, Department of Consumer Protection, and Department of M...
Our analysis included 1412 opioid-detected overdose deaths. 47 % received an opioid or benzodiazepine 90 days prior to death; 36 % received an opioid and 27 % received a benzodiazepine. Concordance be...
Our results suggest medically supplied opioids and benzodiazepines potentially contributed to a substantial number, though minority, of opioid-detected deaths during the study period. Efforts to reduc...
Access to anaesthesia and surgical care is a major problem for people living in Sub-Saharan Africa. In this region, ketamine is critical for the provision of anaesthesia care. However, efforts to cont...
This research is a mixed-methods study, comprising of a cross-sectional survey at the hospital level in Rwanda, and key informant interviews with experts on anaesthesia care in Sub-Saharan Africa. Dat...
The survey conducted in Rwanda found that availability of ketamine and propofol was comparable at around 80%, while thiopental and inhalational agents were available at only about half of the hospital...
Ketamine is critical for the provision of anaesthesia care in Sub-Saharan Africa, and its scheduling would have a significantly negative impact on its availability for anaesthesia care....
Mandatory COVID-19 shelter-in-place (SIP) orders have been imposed to fight the pandemic. They may also have led to unintended consequences of increased use of controlled substances especially among r...
Call counts received by the poison control centers between October 19, 2019 and July 6, 2020 due to exposure to controlled substance (methamphetamine, opioids, cocaine, benzodiazepines, and other narc...
During the study period, 2,649 counties in the United States had mandatory SIP orders. The rate of calls reporting exposure to any of the aforementioned controlled substances among the rural counties ...
The mandatory SIP orders may have had an unintended consequence of exacerbating the use of controlled substances at home in rural communities relative to urban communities....
Patients with substance use disorder (SUD) have high prevalence of lifestyle-related comorbidities. Physical exercise is known to yield substantial prophylactic impact on disease and premature mortali...
This study will recruit 40 in-patients of mixed genders, aged 18-70 years. Participants will be block allocated to low-dose or high-dose training, encompassing 24 high-intensity interval and maximal s...
This protocol is in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement. All participants will sign a written informed consent. The Regional Committee of M...
NCT04065334....
The mechanisms underlying drug addiction remain nebulous. Furthermore, new psychoactive substances (NPS) are being developed to circumvent legal control; hence, rapid NPS identification is urgently ne...
New psychoactive substances (NPS) are not controlled under the Single Convention on Narcotic Drugs of 1961 or the 1971 Convention, but they may pose a public health threat. Knowledge of the main prope...
We carried out a literature review collecting information on the acute, chronic, and post-mortem toxicity of these classes of NSP. We searched info in five scientific databases considering works from ...
Results have shown a general lack of studies in this field given that many NPS have not had their toxicity evaluated. We observed a significant difference in the volume of data concerning acute and ch...
More in-depth information about the main threats involving NPS use are needed....
To examine the association between electronic prescribing of controlled substances (EPCS) and controlled substance prescription patterns in U.S. emergency departments (ED)....
We conducted cross-sectional analysis at both the ED level and visit level, using the 2016-2017 National Hospital Ambulatory Medical Care Surveys....
The sample included 24,296 visits to 316 EDs, 45% of which utilized EPCS. Pain-related visits were associated with significantly higher odds of prescriptions for any controlled substances (OR = 1.52; ...
While EPCS transmits prescriptions directly to pharmacies in order to reduce drug diversion problems, the results indicated no significant association between EPCS use and prescriptions for Schedule I...
EPCS does not appear to deter Schedule II controlled substances prescription including opioids in an ED visit. It may facilitate any and Schedule III controlled substance prescriptions when pain was i...
Abuse of physician prescribed opioids contributes to health and economic burdens associated with dependency, overdose, and death. Since the 1900s, the United States (U.S.) Congress has legislated use ...